Abstract
Simple SummaryCardiovascular disease and cancer are the leading causes of hospitalization and mortality in high-income countries. Studies of myocardial infarction show a disadvantage for the female sex in terms of survival and development of heart failure after myocardial infarction. The extent to which this also applies to the co-occurrence of coronary heart disease and cancer was investigated and analyzed here in large registry studies. Particular attention has been paid to the four most common cancers and hematologic diseases associated with coronary artery disease requiring treatment.Cardiovascular disease and cancer remain the leading causes of hospitalization and mortality in high-income countries. Survival after myocardial infarction has improved but there is still a difference in clinical outcome, mortality, and developing heart failure to the disadvantage of women with myocardial infarction. Most major cardiology trials and registries have excluded patients with cancer. As a result, there is only very limited information on the effects of coronary artery disease in cancer patients. In particular, the outcomes in women with cancer and coronary artery disease and its management remain empiric. We reviewed studies of over 27 million patients with coronary artery disease and cancer. Our review focused on the most important types of cancer (breast, colon, lung, prostate) and hematological malignancies with particular attention to sex-specific differences in treatment and prognosis.
Highlights
Cardiovascular disease and cancer remain the leading causes of hospitalization and mortality in high-income countries
This study showed that the impact of stent implantation on in-hospital mortality decreased over time and has not been significant since 2008 [12]
Cancer and cardiovascular disease are closely related in their origins [4]
Summary
Cardiovascular disease and cancer remain the leading causes of hospitalization and mortality in high-income countries. Since the 1980s, the incidence of acute myocardial infarction (AMI) and associated mortality has steadily declined in these countries [1]. The number of cancer patients suffering from hemodynamically relevant coronary artery disease increased [2,3]. This is not surprising since cancer and cardiovascular disease share some of the same risk factors such as inflammation and oxidative stress [4]. The CANTOS trial of the interleukin-1ß inhibitor canakinumab demonstrated that a decrease in inflammation, as measured by a decrease in high-sensitivity C-reactive protein (hsCRP), led to a decrease in myocardial infarction, stroke, or cardiovascular death and, in particular, a decrease in the incidence of cancer [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
